CN1729183A - 新颖的拉帕酮化合物及其使用方法 - Google Patents

新颖的拉帕酮化合物及其使用方法 Download PDF

Info

Publication number
CN1729183A
CN1729183A CNA2003801066171A CN200380106617A CN1729183A CN 1729183 A CN1729183 A CN 1729183A CN A2003801066171 A CNA2003801066171 A CN A2003801066171A CN 200380106617 A CN200380106617 A CN 200380106617A CN 1729183 A CN1729183 A CN 1729183A
Authority
CN
China
Prior art keywords
unsubstituted
replacement
compound
alkyl
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801066171A
Other languages
English (en)
Chinese (zh)
Inventor
江志伟
达谢瑞瑟·瑞蒂
塞缪尔·K·阿克曼
琼·萨尔维西
孙显高
李有志
李畅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of CN1729183A publication Critical patent/CN1729183A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CNA2003801066171A 2002-11-18 2003-11-18 新颖的拉帕酮化合物及其使用方法 Pending CN1729183A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42728302P 2002-11-18 2002-11-18
US60/427,283 2002-11-18
US10/622,854 2003-07-17
USPCT/US03/22631 2003-07-17

Publications (1)

Publication Number Publication Date
CN1729183A true CN1729183A (zh) 2006-02-01

Family

ID=34375156

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801066171A Pending CN1729183A (zh) 2002-11-18 2003-11-18 新颖的拉帕酮化合物及其使用方法

Country Status (12)

Country Link
US (1) US20040266857A1 (OSRAM)
EP (1) EP1567515A4 (OSRAM)
JP (1) JP2006508147A (OSRAM)
CN (1) CN1729183A (OSRAM)
AR (1) AR056613A1 (OSRAM)
AU (1) AU2003295738A1 (OSRAM)
BR (1) BR0316296A (OSRAM)
CA (1) CA2506340A1 (OSRAM)
EA (1) EA200500849A1 (OSRAM)
MX (1) MXPA05005314A (OSRAM)
TW (1) TW200510367A (OSRAM)
WO (1) WO2004045557A2 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050033A2 (en) 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers
CA2546445A1 (en) 2003-11-26 2005-06-16 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
WO2005082359A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of pancreatic cancer
CA2555941A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treatment of colon cancer
JP2007523191A (ja) * 2004-02-20 2007-08-16 アークル・インコーポレーテツド 血液腫瘍の治療のためのβ−ラパコンの使用
WO2005082353A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating or preventing cancer
CA2556823A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of lung cancer
JP2007523192A (ja) * 2004-02-20 2007-08-16 アークル・インコーポレーテツド 広域スペクトラム抗癌剤としてのβ−ラパコンの使用
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
CA2583700A1 (en) * 2004-08-11 2006-02-23 Arqule, Inc. Quinone prodrug compositions and methods of use
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
EP1836320A2 (en) 2005-01-07 2007-09-26 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
WO2006128120A2 (en) * 2005-05-26 2006-11-30 Arqule, Inc. Novel lapachone compounds and methods of use thereof
WO2007139569A1 (en) * 2006-05-26 2007-12-06 Arqule, Inc. Novel lapachone compounds and methods of use thereof
TW200824692A (en) 2006-08-21 2008-06-16 Arqule Inc Novel lapachone compounds and methods of use thereof
EP2137168B1 (en) * 2007-03-16 2016-09-14 Lankenau Institute for Medical Research Novel ido inhibitors and methods of use thereof
MX2009011822A (es) 2007-04-30 2010-01-14 Arqule Inc Hidroxi sulfonatos de compuestos de quinonicos y sus usos.
WO2009051752A1 (en) * 2007-10-16 2009-04-23 Arqule, Inc. Novel lapachone compounds and methods of use thereof
KR101405823B1 (ko) 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
KR20090073381A (ko) * 2007-12-31 2009-07-03 주식회사 머젠스 심장질환의 치료 및 예방을 위한 약제 조성물
EP2575740A4 (en) * 2010-06-01 2015-09-30 Belle Aire Fragrances Inc METHOD AND PRODUCT FOR COMBATTING ORAL ODORS
US10829427B2 (en) 2015-12-18 2020-11-10 The Board Of Regents Of The University Of Texas System Naphthoquinones, pro-drugs, and methods of use thereof
KR101735275B1 (ko) 2016-12-20 2017-05-16 아주대학교산학협력단 베타-라파촌을 포함하는 수면 장애 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2011455B (en) * 1977-12-21 1982-03-03 Ici Ltd Chemical process
US5346917A (en) * 1991-06-10 1994-09-13 Sterling Winthrop Inc. Thioxanthenone antitumor agents
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
US5883270A (en) * 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
JP2005538981A (ja) * 2002-07-17 2005-12-22 アーキュル， インコーポレイテッド 活性化チェックポイント療法およびこれらの使用方法

Also Published As

Publication number Publication date
EP1567515A4 (en) 2008-04-23
AU2003295738A1 (en) 2004-06-15
AR056613A1 (es) 2007-10-17
WO2004045557A2 (en) 2004-06-03
JP2006508147A (ja) 2006-03-09
WO2004045557A3 (en) 2004-08-12
EA200500849A1 (ru) 2006-02-24
BR0316296A (pt) 2005-12-13
CA2506340A1 (en) 2004-06-03
MXPA05005314A (es) 2005-10-19
EP1567515A2 (en) 2005-08-31
TW200510367A (en) 2005-03-16
US20040266857A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
CN1729183A (zh) 新颖的拉帕酮化合物及其使用方法
US6316470B1 (en) Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
CN1176080C (zh) 茚并一,萘并一和苯并环庚二氢噻唑衍生物,它们的制备以及它们作为降低食欲药的用途
CN1150197C (zh) 作为细胞毒性抗肿瘤剂的萘并噻吩和二氢苯并噻吩的衍生物
JPH03151374A (ja) 新規化合物、その製法及びそれを含む医薬組成物
CN1142227A (zh) 新的噻唑烷-4-酮衍生物
EP0553016B1 (fr) Nouveaux amides et sulfonamides naphtaleniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
HK1045809A1 (en) Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylaxis or treatment of obesity
CN1054123C (zh) 氨基甲酸衍生物的制备方法
HK1043117B (zh) 多環的2-氨基噻唑體系、它們的製備方法和包含這些化合物的藥物
JP2002501475A (ja) 製剤学的に活性な化合物とその使用
EP2964623A1 (en) Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals
CN1152026C (zh) 多环的2-氨基二氢噻唑体系、它们的制备方法和它们作为药物的用途
JP4508531B2 (ja) ベンゾオキサチエピン誘導体およびその医薬としての用途
JPWO2002064601A1 (ja) ジカルバ−クロゾ−ドデカボラン誘導体
CN1557814A (zh) 高喜树碱类化合物及其制备方法和用途
CN103664804B (zh) 吡考他胺类似物、制备方法及其应用
US6166205A (en) 2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine . D.sub4 receptor subtype ligands
US6486164B2 (en) 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
JPH03291261A (ja) ω−アミノ−フェニルアルカノニトリル誘導体
WO1999064425A1 (en) Substituted thienocycloalkylpyrazoles: dopamine receptor subtype specific ligands
WO1999064396A1 (en) Substituted 1-aryl-3-benzylaminopyrrolidine: dopamine receptor subtype specific ligands
US6034252A (en) Substituted thienocycloalkylpyrazoles: dopamine receptor subtype specific ligands
KR20050089007A (ko) 신규한 라파콘 화합물 및 이의 사용 방법
WO2000012500A2 (en) 2-aryl-4-(1-[4-heteroaryl]piperazin-1-yl) methylimidazoles: dopamine d4 receptor subtype ligands

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication